Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma

Trial Profile

Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2016

At a glance

  • Drugs DTRMWXHS 12 (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Zhejiang DTRM Biopharma
  • Most Recent Events

    • 05 Oct 2016 New trial record
    • 21 Sep 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top